États-Unis · Plateformes & données · Morningstar

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Publié par Morningstar · États-Unis il y a 14 h

Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

À lire aussi

Advanced Micro Devices, Inc. $AMD Stake Lessened by Atlatl Advisers LLC

The Next AI Infrastructure Winner Isn't a Memory Stock. It's This.

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

3 UK Consumer Staples Shares Investors May Watch As Confidence Slumps

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Hooters closes 35-year-old location after shutting 55 restaurants

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Partager

À lire aussi

Advanced Micro Devices, Inc. $AMD Stake Lessened by Atlatl Advisers LLC

The Next AI Infrastructure Winner Isn't a Memory Stock. It's This.

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

3 UK Consumer Staples Shares Investors May Watch As Confidence Slumps

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Hooters closes 35-year-old location after shutting 55 restaurants